Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline
Navneet Singh(Post Graduate Institute of Medical Education and Research), Ishmael Jaiyesimi(Beaumont Hospital, Royal Oak), Julie R. Brahmer(Johns Hopkins University), Hirva Mamdani(Wayne State University), Dharamvir Jain(University of Louisville), Bryan J. Schneider(Georgetown University), Elizabeth Blanchard(American Society of Clinical Oncology), Paul J. Hesketh(Lahey Hospital and Medical Center), Rami Y. Haddad(American Society of Clinical Oncology), Rafael Rosell(Hospital Universitario Dexeus), Pamela R. Moffitt(American Society of Clinical Oncology), Joan H. Schiller(Virginia Department of Health), Gregory J. Riely(Memorial Sloan Kettering Cancer Center), Paul Celano(Greater Baltimore Medical Center), Tanyanika Phillips(Georgetown University), Gregory A. Masters(Christiana Care Health System), Sarah Temin(Virginia Cancer Institute), Ivy B. Elkins(American Society of Clinical Oncology), David H. Johnson(Texas A&M University), Sherman Baker(American Society of Clinical Oncology), Narjust Duma(Rutgers, The State University of New Jersey), Natasha B. Leighl(Princess Margaret Cancer Centre), Andrew Robinson(American Society of Clinical Oncology), David R. Spigel(Sarah Cannon)
Cited by 116
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k